西那卡塞联合氯雷他定治疗维持性血液透析患者皮肤瘙痒的临床疗效观察

摘要
图/表
参考文献
相关文章 (1)

全文:PDF(1802 KB)HTML(1 KB)
输出:BibTeX|EndNote(RIS)

摘要目的：观察西那卡塞联合氯雷他定治疗维持性血液透析（MHD）患者皮肤瘙痒的临床疗效。方法：选取2020年8月―2021年8月在本院血液净化中心规律行血液透析并发皮肤瘙痒患者80例,随机分为对照组和观察组,每组40例。对照组给予氯雷他定治疗,观察组患者在对照组基础上联合西那卡塞治疗。连续治疗3个月后,比较两组患者血清因子（BUN、Scr）、临床疗效、视觉模拟评分（VAS）、改良 Duo氏瘙痒评分、匹兹堡睡眠质量指数问卷评分（PSQI）及不良反应发生情况。结果：治疗前后两组患者血清BUN、Scr无明显差异;观察组患者临床疗效显著优于对照组;观察组患者VAS评分、改良 Duo氏瘙痒评分及PSQI评分较对照组显著降低。结论：西那卡塞联合氯雷他定治疗MHD患者皮肤瘙痒疗效显著,可有效缓解MHD患者的皮肤瘙痒症状,同时改善患者的生活及睡眠质量,值得临床推广。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	蒋亚芬
	刘沧桑

关键词：血液透析,皮肤瘙痒,西那卡塞,氯雷他定

Abstract：ObjectiveTo observe the clinical efficacy of cinacalcet combined with loratadine in the treatment of skin pruritus in maintenance hemodialysis (MHD) patients.Methods80 patients with regular hemodialysis and skin pruritus in our hospital's blood purification center from August 2020 to August 2021 were selected and randomly divided into a control group and an observation group, with 40 cases in each group. The control group was treated with loratadine, while the observation group was treated with cinacalcet combined with loratadine on the basis of the control group. After 3 months of continuous treatment, serum factors (BUN, Scr), clinical efficacy, visual analogue score (VAS), modified Duo itch score, Pittsburgh Sleep Quality Index questionnaire score (PSQI) and adverse reactions were compared between the two groups.ResultsCompared with before treatment, there was no significant difference in serum BUN and Scr between the two groups after treatment. The clinical efficacy of the observation group was significantly better than that of the control group, with a statistically significant difference. The VAS score, modified Duo itch score and PSQI score of patients in the observation group were significantly lower than those in the control group.ConclusionCinacalcet combined with loratadine has a significant effect on MHD skin pruritus and can effectively relieve skin pruritus symptoms in MHD patients while improving their quality of life and sleep quality. It is worth promoting clinically.

Key words：hemodialysis skin pruritus cinacalcet loratadine

收稿日期:2022-10-21

中图分类号:

R692.5

基金资助:湖南省卫生健康委科研计划项目（D202303057575）

通讯作者:刘沧桑,E-mail：16188807@qq.com

引用本文:

蒋亚芬, 刘沧桑. 西那卡塞联合氯雷他定治疗维持性血液透析患者皮肤瘙痒的临床疗效观察[J]. journal1, 2023, 20(2): 117-119. JIANG Yafen, LIU Cangsang. Clinical observation on the efficacy of cinacalcet combined with Loratadine in treating skin pruritus in maintenance hemodialysis patients. journal1, 2023, 20(2): 117-119.

链接本文:

http://yxb.hunnu.edu.cn/CN/或http://yxb.hunnu.edu.cn/CN/Y2023/V20/I2/117

[1] 陈宗英, 谢席胜. 尿毒症性皮肤瘙痒研究现状[J]. 中国中西医结合肾病杂志, 2017, 18(9): 841-843.
[2] Rayner HC, Larkina M, Wang MA, et al.International comparisons of prevalence, awareness, and treatment of pruritus in people on hemodialysis[J]. Clin J Am Soc Nephrol, 2017, 12(12): 2000-2007.
[3] 戴佳成, 王怡, 韩世盛. 尿毒症皮肤瘙痒症发病机制的研究进展[J]. 医学综述, 2022, 28(13): 2562-2566.
[4] 毕丹. 维持性血液透析患者尿毒症性皮肤瘙痒的研究进展[J]. 中国冶金工业医学杂志, 2022, 39(2): 138-140.
[5] 中国医师协会皮肤科分会变态反应性疾病专业委员会. 慢性瘙痒管理指南 (2018版)[J]. 中华皮肤科杂志, 2018, 51(7): 481-485.
[6] Satoh T, Yokozeki H, Murota H, et al.2020 guidelines for the diagnosis and treatment of cutaneous pruritus[J]. J Dermatol, 2021, 48(9): e399-e413.
[7] 杨春丽. 西那卡塞联合硫代硫酸钠治疗维持性血液透析患者顽固性皮肤瘙痒的临床研究[J]. 吉林医学, 2022, 43(3): 717-718.
[8] 王华, 梁辑, 詹元英, 等. 硫代硫酸钠联合氯雷他定治疗尿毒症瘙痒症的疗效分析[J]. 中华保健医学杂志, 2022, 24(2): 122-124.
[9] 刘钊, 廖艳, 唐俊. 维持性血液透析患者皮肤瘙痒相关发病机制及治疗研究进展[J]. 中国医学创新, 2022, 19(15): 170-174.
[10] Ur Rehmani I, Chohant TA, Bukhsh A, et al.Impact of Pruritus on Sleep Quality of Hemodialysis Patients: A Systematic Review and Meta-Analysis[J]. Medicina (Kaunas), 2019, 55(10): 699.
[11] Mathur V, Kumar J,Carwford P,et al.A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Nalbuphine ER Tablets for Uremic Pruritus[J].Am J Nephrol, 2017, 46(6): 450-458.
[12] 刘璐, 甄路路, 任美娟, 等. 地氯雷他定治疗荨麻疹的临床综合评价[J]. 药学与临床研究, 2022, 33(10): 1240-1246.
[13] 朱江浩, 黄丽绸, 赖灵娇. 氯雷他定对维持性血液透析并发皮肤瘙痒患者瘙痒症状及睡眠质量的影响[J]. 实用医技杂志, 2020, 27(2): 218-220.
[14] 鞠延娇, 尤艳明, 谢志强. 加巴喷丁及普瑞巴林治疗慢性瘙痒的研究进展[J]. 中国中西医结合皮肤性病学杂志, 2017, 16(4): 373-376.
[15] 唐利, 张家丽, 廖常彬, 等. 西那卡塞联合小剂量骨化三醇治疗维持性血液透析患者中重度继发性甲状旁腺功能亢进症的疗效观察[J]. 当代医学, 2019, 25(32): 20-23.
[16] Kuczera P, Adamczak M, Więcek A.Treatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism[J]. BMC Nephrol, 2016, 17(1): 176.
[17] 周凌辉, 张恒远, 斐娟, 等. 长疗程西那卡塞治疗维持性血液透析患者难治性继发性甲状旁腺功能亢进症的临床观察[J]. 中国全科医学, 2018, 21(8): 989-992.